This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutTherapeutic IndicationsRheumatoid arthritisJuvenile idiopathic arthritisPsoriatic arthritisAxial spondyloarthritisPlaque psoriasis & Paediatric plaque psoriasisMechanism of actionMechanism of actionDosingDosingRheumatoid arthritis, psoriatic arthritis & axial spondyloarthritisJuvenile idiopathic arthritisPlaque psoriasisPaediatric plaque psoriasisAdministration & storageAdministrationMYCLIC®StorageEfficacy & SafetyEfficacy & SafetyRheumatoid arthritisAxial spondyloarthritisPsoriatic arthritisPlaque psoriasisJuvenile idiopathic arthritisSupport & ResourcesMaterials
The Enbrel® MYCLIC® 
​​​​​​​Auto-injectorMYCLIC offers greater flexibility for administration of Enbrel1,2 Associated with greater independence1-4

Self-administration of Enbrel increased from 66% with the pre-filled syringe to 93% with MYCLIC*2

Easier to use2

93% of patients found MYCLIC easier to use than the pre-filled syringe*2​​​​​​​

Better tolerated2

Pain on injection was significantly reduced with mean VAS scores of 1.77 for MYCLIC vs 2.91 for the Enbrel pre-filled syringe (p<0.001)*2

Preferred by patients2

94.2% of patients chose MYCLIC over the pre-filled syringe as their preferred delivery device*2

Among 104 patients diagnosed with rheumatoid arthritis (56%), psoriatic arthritis (30%) or ankylosing spondylitis (14%) who were switched from the Enbrel 50 mg pre-filled syringe to the MYCLIC Auto-injector. Patients answered questions during an interview 2 months after switching.2VAS: Visual analogue scale.​​​​​​​ Enbrel Summary of Product Characteristics and Package Leaflet.
Borrás-Blasco J, et al. Expert Opin Biol Ther. 2013;13:1103-8.Boeri M, et al. Patient Prefer Adherence. 2019;13:1093-110.Larsson I, et al. Int J Qualitative Stud Health Well-being. 2010;5. DOI: 10.3402/qhw.v5i2.5146.Administration & storage

Legal Category: S1A
Further information is available upon request

PP-ENB-IRL-0271 May 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.
PP-UNP-IRL-0176. January 2023